Premium
Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study
Author(s) -
Bedini Amedeo V.,
Tavecchio Luca,
Milani Franco,
Gramaglia Alberto,
Spreafico Carlo,
Marchianò Alfonso,
Ravasi Gianni
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910115)67:2<357::aid-cncr2820670207>3.0.co;2-9
Subject(s) - medicine , radiation therapy , regimen , surgery , cisplatin , carcinoma , lung , infusion therapy , radiology , chemotherapy
Fifty patients with non resectable and/or inoperable bronchogenic carcinoma were entered into a feasibility study of cisplatin (CDDP) given in continuous infusion with concurrent radiation therapy. The radiation therapy regimen consisted of 2 Gy given 5 days a week in the first 3 and last 2 weeks of a 7‐week split course (50 Gy of total dose). The CDDP (daily dose of 4 to 6 mg/m 2 ) was administered to cover the days of radiation treatment by means of a central venous catheter and a portable pump. Less than 1% of predicted duration of infusion was lost due to complications related to venous access and pump. Toxicity was moderate. The overall probability of a locoregional major response (complete + partial) within 1 month after treatment completion was 86%. Twenty‐three patients underwent resection. The 1‐year actuarial probability of survival was 64%. The high response and survival rates warrant further studies on concurrent CDDP continuous infusion and radiation therapy in inoperable lung carcinoma.